Table 4.

Multivariate analysis of factors associated with risk of NRM, acute GvHD, chronic GvHD, relapse, PFS and OS.

Variable	HR (95% Confidence interval)	P-value
Non relapse mortalitya
MUD	Ref	Poverall=0.08
UCB	1.22 (0.87-1.72)	0.24
MMUD	1.32 (1.03-1.69)	0.02
MMUD vs. UCB	1.07 (0.76-1.52)	0.68
Grade II-IV acute GvHDb
MUD	Ref	Poverall<0.001
UCB	0.68 (0.46-1.00)	0.050
MMUD	1.44 (1.18-1.75)	<0.001
MMUD vs UCB	2.12 (1.52-2.95)	<0.001
Chronic GvHDc
MUD	Ref	Poverall<0.001
UCB	0.35 (0.21-0.56)	<0.001
MMUD	1.15 (0.90-1.48)	0.240
MMUD vs UCB	3.32 (1.99-5.54)	<0.001
Relapsed
MUD	Ref	Poverall=0.11
UCB	1.08 (0.72-1.63)	0.70
MMUD	0.75 (0.58-0.98)	0.03
MMUD vs UCB	0.69 (0.42-1.14)	0.15
Progression-free survivale
MUD	Ref	Poverall=0.24
UCB	1.22 (0.96-1.54)	0.09
MMUD	1.07 (0.88-1.29)	0.49
MMUD vs UCB	0.88 (0.67-1.13)	0.31
Overall Survivalf
MUD	Ref	Poverall=0.16
UCB	1.14 (0.89-1.47)	0.29
MMUD	1.19 (0.98-1.45)	0.08
MMUD vs UCB	1.04 (0.77-1.40)	0.77

Abbreviations: HCT hematopoietic cell transplantation, UCB umbilical cord blood; MUD matched unrelated donor, MMUD 1 Ag or allele mismatched unrelated donor, GvHD graft versus host disease, ATG antithymocyte globulin, CsA cyclosporine, MAC myeloablative conditioning, RIC reduced intensity conditioning.

Other prognostic factors in the models

^aAge, time from diagnosis to HCT, race, conditioning regimen, prior auto HCT, & year of HCT

^bATG/alemtuzumab use, GvHD prophylaxis, time from diagnosis to HCT, & disease status.

^cATG/alemtuzumab use

^dATG/alemtuzumab use

^eYear of HCT

^fAge, time from diagnosis to HCT, conditioning regimen, & year.